Association between Circulating Growth Differentiation Factor 15 and Cirrhotic Primary Biliary Cholangitis
Joint Authors
Li, Zhanyi
Liu, Yu
Li, Xiangyong
Wu, Yuankai
Yang, Fangji
Mo, Qiwan
Chong, Yutian
Source
Issue
Vol. 2020, Issue 2020 (31 Dec. 2020), pp.1-11, 11 p.
Publisher
Hindawi Publishing Corporation
Publication Date
2020-10-29
Country of Publication
Egypt
No. of Pages
11
Main Subjects
Abstract EN
Primary biliary cholangitis (PBC) is a common condition that usually shows a progressive course towards cirrhosis without adequate treatment.
Growth differentiation factor 15 (GDF15) plays multiple roles in various pathological conditions.
The overall role of circulating GDF15 in cirrhotic PBC requires further investigation.
Twenty patients with cirrhotic PBC, 26 with non-cirrhotic PBC, and 10 healthy subjects were enrolled between 2014 and 2018, and the serum levels of GDF15 were measured via enzyme immunoassay.
The correlations between serum GDF15, weight, biochemical parameters, and the prognosis were analysed.
Serum levels of GDF15 were significantly higher in cirrhotic PBC patients than in non-cirrhotic PBC patients or healthy controls (p=0.009 and p<0.001, respectively).
The circulating GDF15 levels strongly correlated with weight changes (r=−0.541, p=0.0138), albumin (r=−0.775, p<0.0001), direct bilirubin (r=−0.786, p<0.0001), total bile acids (r=0.585, p=0.007), and C-reactive protein (r=0.718, p=0.0005).
Moreover, circulating GDF15 levels strongly correlated with the Mayo risk score (r=0.685, p=0.0009) and Model for End-stage Liver Disease score (r=0.687, p=0.0008).
Determined by the area under the receiver operating characteristic curves, the overall diagnostic accuracies of GDF15 were as follows: cirrhosis=0.725 (>3646.55 pg/mL, sensitivity: 70.0%, specificity: 69.2%), decompensated cirrhosis=0.956 (>4073.30 pg/mL, sensitivity: 84.62%, specificity: 100%), and cirrhotic biochemical non-responders = 0.835 (>3479.20 pg/mL, sensitivity: 71.43%, specificity: 92.31%).
GDF15 may be a useful and integrated biochemical marker to evaluate not only the disease severity and prognosis but also the nutrition and response to treatment of cirrhotic PBC patients, and its overall performance is satisfactory.
Therapy targeting GDF15 is likely to benefit cirrhotic PBC patients and is worth further research.
American Psychological Association (APA)
Li, Zhanyi& Liu, Yu& Li, Xiangyong& Wu, Yuankai& Yang, Fangji& Mo, Qiwan…[et al.]. 2020. Association between Circulating Growth Differentiation Factor 15 and Cirrhotic Primary Biliary Cholangitis. BioMed Research International،Vol. 2020, no. 2020, pp.1-11.
https://search.emarefa.net/detail/BIM-1134537
Modern Language Association (MLA)
Li, Zhanyi…[et al.]. Association between Circulating Growth Differentiation Factor 15 and Cirrhotic Primary Biliary Cholangitis. BioMed Research International No. 2020 (2020), pp.1-11.
https://search.emarefa.net/detail/BIM-1134537
American Medical Association (AMA)
Li, Zhanyi& Liu, Yu& Li, Xiangyong& Wu, Yuankai& Yang, Fangji& Mo, Qiwan…[et al.]. Association between Circulating Growth Differentiation Factor 15 and Cirrhotic Primary Biliary Cholangitis. BioMed Research International. 2020. Vol. 2020, no. 2020, pp.1-11.
https://search.emarefa.net/detail/BIM-1134537
Data Type
Journal Articles
Language
English
Notes
Includes bibliographical references
Record ID
BIM-1134537